ReviewCancer medicine2024
Romiplostim in chemotherapy-induced thrombocytopenia: A review of the literature.
Review in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07586813 (A Prospective, Randomized, Open-Label, Controlled Study of Romiplostim N01 Combined With All-Trans Retinoic Acid Versus Romiplostim N01 Alone for Persistent Isolated Chemotherapy-Induced Thrombocytopenia in Patients With Complete Remission of Gastrointestinal Solid Tumors), which is not on this map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective, Randomized, Open-Label, Controlled Study of Romiplostim N01 Combined With All-Trans Retinoic Acid Versus Romiplostim N01 Alone for Persistent Isolated Chemotherapy-Induced Thrombocytopenia in Patients With Complete Remission of Gastrointestinal Solid Tumors
Who cites it
14 citing papers in PubMed.
- Romiplostim for chemotherapy induced thrombocytopenia in pediatric cancers.British journal of cancer · 2026Article
- Avatrombopag Versus Placebo for Persistent Chemotherapy-Induced Thrombocytopenia in GI Cancers: The Phase II ACT-GI Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Article
- Avatrombopag Reduces Platelet Transfusion Requirement in Thrombocytopenia Subsequent to Antineoplastic Therapies in Haematological Patients: The Experience of a Tertiary Centre.Journal of clinical medicine · 2026Article
- A novel nomogram to predict length of stay in patients undergoing pylorus-preserving pancreaticoduodenectomy: A retrospective study.Medicine · 2026Observational
- The evolving landscape of platelet therapy: risks, innovations, and clinical judgment.Annals of hematology · 2026Review
- Romiplostim for refractory chemotherapy-induced thrombocytopenia in a long-term survivor of limited-stage small cell lung cancer: a case report.Frontiers in oncology · 2026Article
- Romiplostim N01 accelerates platelet engraftment in autologousstem cell transplantation using non-cryopreserved peripheral blood stem cells for plasma cell neoplasms.Frontiers in immunology · 2026Article
- Anticoagulant therapy in patients with cancer and thrombocytopenia.Journal of thrombosis and thrombolysis · 2025Review
- Understanding Chemotherapy-Induced Thrombocytopenia: Implications for Gastrointestinal Cancer Treatment.Current oncology (Toronto, Ont.) · 2025Review
- Should thrombopoietin receptor agonists be used for chemotherapy-induced thrombocytopenia?Research and practice in thrombosis and haemostasis · 2025Article
- Cancer treatment-induced thrombocytopenia: diagnosis, mechanisms and management.Frontiers in immunology · 2025Review
- Acute myocardial infarction induced by avatrombopag: a case report.Frontiers in pharmacology · 2025Article
- Let It Grow: The Role of Growth Factors in Managing Chemotherapy-Induced Cytopenia.Current oncology (Toronto, Ont.) · 2024Review
- Romiplostim in chemotherapy-induced thrombocytopenia: A review of the literature.Cancer medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Chemotherapy-induced thrombocytopenia (CIT) is a common challenge of cancer therapy and can lead to chemotherapy dose reduction, delay, and/or discontinuation, affecting relative dose intensity, and possibly adversely impacting cancer care. Besides changing anticancer regimens, standard management of CIT has been limited to platelet transfusions and supportive care. Use of the thrombopoietin receptor agonist romiplostim, already approved for use in immune thrombocytopenia, has shown promising signs of efficacy in CIT. In a phase 2 prospective randomized study of solid tumor patients with platelet counts <100 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.